Adicet Bio Inc
Company Profile
Business description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Contact
131 Dartmouth Street
3rd Floor
BostonMA02116
USAT: +1 650 503-9095
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
152
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,321.10 | 10.80 | -0.12% |
CAC 40 | 8,258.86 | 52.79 | 0.64% |
DAX 40 | 24,330.03 | 71.23 | 0.29% |
Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
FTSE 100 | 9,426.99 | 23.42 | 0.25% |
HKSE | 25,813.59 | 213.96 | -0.82% |
NASDAQ | 22,953.67 | 36.88 | -0.16% |
Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
S&P 500 | 6,735.35 | 0.22 | 0.00% |
S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
SSE Composite Index | 3,912.60 | 3.74 | -0.10% |